Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | FTO | Q9C0B1 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26472361 | 0.91 | MAPT (0.59) | HPGDTDP1CYP3A4ALDH1A1HIF1A | |
| SCHEMBL15435609 | 0.91 | HPGD (0.51) | HPGDTDP1CYP3A4ALDH1A1HIF1A | |
| SCHEMBL20353110 | 0.91 | ALDH1A1 (0.52) | HPGDTDP1CYP3A4ALDH1A1HIF1A | |
| SCHEMBL9610878 | 0.86 | FTO (0.66) | HPGDTDP1CYP3A4ALDH1A1HIF1A | |
| SCHEMBL31580046 | 0.86 | FTO (0.66) | HPGDTDP1CYP3A4ALDH1A1HIF1A | |
| SCHEMBL11964686 | 0.86 | CYP3A4 (0.49) | HPGDTDP1CYP3A4ALDH1A1HIF1A | |
| SCHEMBL17737165 | 0.86 | CYP3A4 (0.49) | HPGDTDP1CYP3A4ALDH1A1HIF1A | |
| SCHEMBL5143698 | 0.85 | ALDH1A1 (0.66) | HPGDTDP1CYP3A4ALDH1A1HIF1A | |
| SCHEMBL12152338 | 0.83 | ALDH1A1 (0.81) | HPGDTDP1CYP3A4ALDH1A1HIF1A | |
| SCHEMBL19769251 | 0.83 | HPGD (0.56) | HPGDTDP1CYP3A4ALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159458-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | AM CHEMICALS LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-10781175-B2 | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates | AM CHEMICALS LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200277260-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | AM CHEMICALS LLC (US) | 2020-09-03 | — | — | US | disclosed |
| US-20180016232-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | AM CHEMICALS LLC (US) | 2018-01-18 | — | — | US | disclosed |
| US-9434763-B2 | Derivatives of pyridinone as inhibitors for tissue transglutaminase | ZEDIRA GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9434763-B2 | Derivatives of pyridinone as inhibitors for tissue transglutaminase | ZEDIRA GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | ZEDIRA GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | ZEDIRA GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| EP-2797892-B1 | PYRIDINONE DERIVATIVES AS TISSUE TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2015-05-27 | — | — | EP | disclosed |
| EP-2687511-A1 | Pyridinone derivatives as tissue transglutaminase inhibitors | Zedira GmbH (DE) | 2014-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | PLPBP, PNPO, PDXK | HPGD 36/4885TDP1 483/4885CYP3A4 362/4885 |
| US-10781175-B2 | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates | NCL, PAICS, RTCB | HPGD 3912/4885TDP1 674/4885CYP3A4 4155/4885 |
| US-20230159458-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | NCL, PAICS, RTCB | HPGD 3912/4885TDP1 674/4885CYP3A4 4155/4885 |
| US-20200277260-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | NCL, PAICS, RTCB | HPGD 3912/4885TDP1 674/4885CYP3A4 4155/4885 |
| US-20180016232-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | NCL, PAICS, RTCB | HPGD 3912/4885TDP1 674/4885CYP3A4 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.